“Global Cancer Immunotherapy market set to grow to $117bn by 2024” says new Visiongain report

21 January 2019
Pharma

Visiongain has launched a new pharma report Global Cancer Immunotherapy Market Forecast 2019-2029: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics.

Immunotherapeutics and targeted therapies are emerging as promising treatment options for various cancer types. In the biological cancer drug category, monoclonal antibodies (mAbs) have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity.

The lead analyst of the report commented "The cancer immunotherapy market remains attractive, as it is a large and growing clinical area with growing incidence of cancer cases, globally. Significant unmet need exists in the cancer market due to the rising need for more compelling clinical evidences and improved patient convenience.

In addition, increased medical education to improve clinical practice, improved care coordination between therapies and sites of care, and enhanced decision tools and practice guidelines are expected to drive future trends and innovations."

Leading companies featured in the report include Adaxic Inc., AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Eli Lilly and Co., Medtronic Plc, Merck & Co., Inc. (Merck), Novartis, Pfizer, Roche

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs.

18 April 2019

Read

“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature.

17 April 2019

Read

“Global Drug Discovery Outsourcing market set to grow to $45bn by 2024” says new Visiongain report

A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services.

16 April 2019

Read

“Global Dermatological Drugs market set to grow to $36bn by 2024” says new Visiongain report

The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas.

15 April 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1